NASDAQ:LUMO - Lumos Pharma Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $29.67
Forecasted Upside: 295.56 %
Number of Analysts: 6
Breakdown:
0 Sell Ratings
0 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$7.50 As of 08/4/2021 01:00 AM ET

▼ -0.15 (-1.96%)

1 month | 3 months | 12 months

Get New Lumos Pharma Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for LUMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LUMO

^$29.67

▲ +295.56% Upside Potential

This price target is based on 6 analysts offering 12 month price targets for Lumos Pharma in the last 3 months. The average price target is $29.67, with a high forecast of $35.00 and a low forecast of $24.00. The average price target represents a 295.56% upside from the last price of $7.50.

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Lumos Pharma.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/11/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/11/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/9/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/7/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/5/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/6/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/5/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/4/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/22/2021	Roth Capital	Lower Price Target	Buy	$51.00 ➝ $35.00	High
7/21/2021	HC Wainwright	Lower Price Target	Buy	$34.00 ➝ $27.00	High
4/13/2021	Jonestrading	Initiated Coverage	Buy	$34.00	High
3/11/2021	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$4.00 ➝ $24.00	High
12/2/2020	Cantor Fitzgerald	Initiated Coverage	Overweight	$32.00	Medium
11/23/2020	HC Wainwright	Boost Price Target	Buy	$33.00 ➝ $34.00	High
8/25/2020	Piper Sandler	Initiated Coverage	Overweight	$26.00	Medium
8/17/2020	Roth Capital	Reiterated Rating	Buy	$51.00	High
8/4/2020	HC Wainwright	Initiated Coverage	Buy		Low
5/1/2020	Roth Capital	Initiated Coverage	Buy		High
4/16/2020	Jefferies Financial Group	Initiated Coverage	Buy	$12.00	Low

(Data available from 8/5/2016 forward)

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.

Today's Range

Now: $7.50

$7.45

$7.63

50 Day Range

MA: $9.85

$7.36

$11.84

52 Week Range

Now: $7.50

$7.33

$36.72

Volume

70,357 shs

Average Volume

52,643 shs

Market Capitalization

$62.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Lumos Pharma?

The following Wall Street analysts have issued research reports on Lumos Pharma in the last twelve months: Cantor Fitzgerald, HC Wainwright, Jonestrading, Piper Sandler, Roth Capital, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for LUMO.

What is the current price target for Lumos Pharma?

6 Wall Street analysts have set twelve-month price targets for Lumos Pharma in the last year. Their average twelve-month price target is $29.67, suggesting a possible upside of 295.6%. Roth Capital has the highest price target set, predicting LUMO will reach $35.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $24.00 for Lumos Pharma in the next year.
View the latest price targets for LUMO.

What is the current consensus analyst rating for Lumos Pharma?

Lumos Pharma currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LUMO will outperform the market and that investors should add to their positions of Lumos Pharma.
View the latest ratings for LUMO.

What other companies compete with Lumos Pharma?

Other companies that are similar to Lumos Pharma include Enochian Biosciences, Ovid Therapeutics, Millendo Therapeutics, Harrow Health, Cogent Biosciences, Fulcrum Therapeutics, Immunic, Infinity Pharmaceuticals, Mustang Bio, NexImmune, Osmotica Pharmaceuticals, Chiasma, Kezar Life Sciences, 180 Life Sciences and Adicet Bio.

How do I contact Lumos Pharma's investor relations team?

Lumos Pharma's physical mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The company's listed phone number is 512-215-2630 and its investor relations email address is [email protected] The official website for Lumos Pharma is www.lumos-pharma.com.